Literature DB >> 30667559

Sequential liver and haematopoietic stem cell transplantation in a case of fulminant hepatitis associated liver failure and aplastic anaemia.

Zeyad Al-Shaibani1, Sreelakshmi Kotha2, Wilson Lam1, Zita Galvin3, Leslie Lilly3, Jeffrey H Lipton1, Arjun Datt Law1.   

Abstract

The management of severe aplastic anaemia is particularly challenging when it occurs in the context of recent liver transplantation. Rapid identification of a suitable donor followed by allogeneic haematopoietic stem cell transplantation is the only curative option. This scenario is often complicated by potentially life-threatening infections that develop as a consequence of immunosuppression. Alternative donor transplantation using suitably matched unrelated donors can be potentially life-saving when suitably matched sibling donors are unavailable. Above all, a dedicated interdisciplinary approach with seamless communication between hepatology, transplant surgery, haematology, and stem cell transplant services is essential to achieving optimal outcomes. Herein, we describe a case of severe hepatitis leading to hepatic failure who was treated with liver transplantation from a deceased donor, and later received an allogeneic haematopoietic stem cell transplantation from a matched unrelated donor for hepatitis-associated aplastic anaemia.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allogeneic blood and marrow transplantation; aplastic anaemia; liver transplantation

Mesh:

Substances:

Year:  2019        PMID: 30667559     DOI: 10.1111/ejh.13213

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  1 in total

1.  Successful Treatment of a 19-Month-Old Boy with Hepatitis Associated Aplastic Anemia by Infusion of Umbilical Cord-Derived Mesenchymal Stromal Cells: A Case Report.

Authors:  Liu Fang; Lim Meikuang; Guo Ye; Chen Xiaojuan; Yang Wenyu; Ruan Min; Chang Lixian; Wang Weiqiang; Han Zhibo; Han Zhongchao; Zhu Xiaofan
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.